Arginine Market: Drivers
Increasing researches on arginine as an adjuvant for the treatment of various diseases is expected to drive growth of the arginine market. For instance, an article published in PLOS One journal in May 2015 suggested that arginine might alter multi-species oral biofilm development and may also break down dental plaque, which could help millions of people in preventing dental decay and gum diseases.
Furthermore, new product development is expected to fuel growth of the arginine market. For instance, in October 2018, Nutrition 21, LLC announced that its clinically substantiated ingredient, Nitrosigine, is now included in Elite Gold NX6 product. Elite Gold NX6 is a polymer of arginine silicate, which is stabilized by inositol. Therefore, the development of Elite Gold NX6 with nitrosigine ingredient will help in boosting nitric oxide levels, which is found to be a key factor in generating greater blood flow and vasodilation in working muscles.
Arginine Market: Restraint
Product recalls for arginine drug packaging is expected to hamper growth of the arginine market. For instance, in November 2017, Therapeutics Goods Administration (TGA) of Australia recalled Apotex Inc.’s Apo-Perindopril Arginine 2.5 mg, 5 mg, and 10 mg tablet batches from the market due to contamination of tablet bottles with dark particles of silica. This contamination was classified as a quality defect. Apo-Perindopril Arginine is indicated for high blood pressure, heart failure or coronary artery disease. Moreover, United Pharmacy recalled two lots of a compounded injectable glutamine/arginine/carnitine product, GAC-12 and GAC-13, in November 2017.
Arginine Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients